Whether genetic risk features such as IKZF1 deletions, which are associated with unfavorable outcomes in BCR::ABL1-positive ALL, also play a role in CML-BP and should be considered in therapy stratification has not been investigated [28]. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.